Does US FDA Need An Independent Commission To Analyze Its Pandemic Response?

Group of outside experts could help the agency determine the pandemic-inspired practices and regulatory changes to keep, former commissioner von Eschenbach says.

Screenshot from FDLI Annual Conference of former commissioners' discussion
Former FDA commissioners Andrew von Eschenbach, Robert Califf and Mark McClellan discuss how the pandemic changed the agency with FDLI President and CEO Amy Comstock Rick. • Source: screenshot

Former commissioner Andrew von Eschenbach suggested an external group may offer the best chance for the US Food and Drug Administration to determine the best lessons learned by lessons from the coronavirus pandemic.

During an 18 May Food and Drug Law Institute Annual Conference session, von Eschenbach, now president of Samaritan Health Initiatives,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Agency Leadership

More from Pink Sheet